Phase III Trial of ASO Therapy for the Treatment of Huntington’s Disease Halted

April 14th, 2021|Categories: Perspectives on Current Science|

Recently, people who have been impacted by Huntington’s disease, their families, and the OTS community were disappointed to learn that the GENERATION HD1 Phase III study of Tominersen was halted based on the recommendation of an unblinded Independent Data Monitoring Committee. Although not based on [...]

Interview with Mark Behlke

March 31st, 2021|Categories: Featured Members|

Mark Behlke, MD, PhDChief Scientific OfficerIntegrated DNA Technologies, Inc. How did you become interested in the field of oligonucleotides?I had always thought that I would pursue a career in academic medicine, but in the Fall of 1995, I was visiting my parents who had moved to [...]

siRNA: From a Powerful Research Tool to Potent Therapeutic Modality

March 30th, 2021|Categories: Perspectives on Current Science|

Earlier this year we celebrated the 20th Anniversary of RNA Interference in Mammalian Cells. In this article, we are going to discuss small interfering RNA (siRNA), a key mechanism that induces gene silencing in the RNAi pathway. siRNAs are highly specific, making them a [...]

The Astonishing History, Controversies, and Game-Changing Uses of CRISPR

March 16th, 2021|Categories: Perspectives on Current Science|

Many of us view CRISPR as an incredibly useful tool. It is even referred to as genetic scissors because CRISPR allows scientists to edit the genes (the DNA) of organisms, from the smallest cells to an entire mammal. Because of its revolutionary impact on life [...]

Go to Top